The journey of a biomarker from analytical and clinical validation to clinical and public health utility is laden with a host of challenges. This opinion piece and innovation analysis presents an approach to biomarker discovery and development with a focus on tissue specificity and disease causality, using the case of hepatic disease.
Get full access to this article
View all access options for this article.
References
1.
DiamandisEP. The failure of protein cancer biomarkers to reach the clinic: Why, and what can be done to address the problem? BMC Med, 2012; 10:87; doi: 10.1186/1741-7015-10-87
HoodL, HeathJR, PhelpsME, et al.Systems biology and new technologies enable predictive and preventative medicine. Science, 2004; 306(5696):640–643; doi: 10.1126/science.1104635
4.
HuangH, WuT, MaoJ, et al.CHI3L1 is a liver-enriched, noninvasive biomarker that can be used to stage and diagnose substantial hepatic fibrosis. OMICS, 2015; 19(6):339–345; doi: 10.1089/omi.2015.0037
5.
HuangX, ZhuangJ, YangY, et al.Diagnostic value of serum Chitinase-3-like protein 1 for liver fibrosis: A meta-analysis. Biomed Res Int, 2022; 2022:3227957; doi: 10.1155/2022/3227957
6.
JiangY, GongW, LiuY, et al.Serum CHI3L1 levels predict overall survival of hepatocellular carcinoma patients after hepatectomy. J Cancer, 2024; 15(19):6315–6325; doi: 10.7150/jca.100791
7.
KernSE. Why your new cancer biomarker may never work: Recurrent patterns and remarkable diversity in biomarker failures. Cancer Res, 2012; 72(23):6097–6101; doi: 10.1158/0008-5472.CAN-12-3232
8.
KramerA, GreenJ, PollardJJr, et al.Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics, 2014; 30(4):523–530; doi: 10.1093/bioinformatics/btt703
9.
LinB, MaY, WuS. Multi-omics and artificial intelligence-guided data integration in chronic liver disease: Prospects and challenges for precision medicine. OMICS, 2022; 26(8):415–421; doi: 10.1089/omi.2022.0079
10.
LinB, WuS. Digital transformation in personalized medicine with artificial intelligence and the internet of medical things. OMICS, 2022; 26(2):77–81; doi: 10.1089/omi.2021.0037
11.
ParkerLA, Chilet-RosellE, Hernandez-AguadoI, et al.Diagnostic biomarkers: Are we moving from discovery to clinical application? Clin Chem, 2018; 64(11):1657–1667; doi: 10.1373/clinchem.2018.292854
12.
SedgewickAJ, BuschurK, ShiI, et al.Mixed graphical models for integrative causal analysis with application to chronic lung disease diagnosis and prognosis. Bioinformatics, 2019; 35(7):1204–1212; doi: 10.1093/bioinformatics/bty769
